ASH 2018 | R2 in the second-line: lenalidomide-rituximab improves PFS in relapsed/refractory NHL

Ian Flinn

Ian Flinn, MD, PhD, of the Tennessee Oncology, Nashville, TN, gives an overview of the Phase III AUGMENT trial (NCT01938001). This study looked at lenalidomide plus rituximab (R2) vs. rituximab monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. Excitingly, R2 improved progression-free survival, as well as an array of secondary endpoints. Here Dr Flinn explains the implications of these results. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video